Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

News | Coronavirus (COVID-19) | September 24, 2020
September 24, 2020 — Analyzing anonymized patient medical records, University of California (UC) San Diego Health...
COVID-19 Therapy Drug Azithromycin May Increase Risk for Cardiac Events

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of...
The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.
News | Coronavirus (COVID-19) | September 11, 2020
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials...
Videos | Pharmaceuticals | September 10, 2020
Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David...
Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial
News | Pharmaceuticals | September 10, 2020
September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation...
The BRACE CORONA trial presented at ESC Congress 2020 is the First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients.
News | Coronavirus (COVID-19) | September 08, 2020
September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin-...
Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

News | Coronavirus (COVID-19) | September 03, 2020
September 3, 2020 — Why so many COVID-19 (SARS-CoV-2) patients get blood clots (thrombosis) remains uncertain. But...
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by...
Dapagliflozin (Farxiga) heart failure drug performs very will to improve outcomes for patients with chronic kidney disease.
News | Pharmaceuticals | July 28, 2020
July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of...
News | Stents | July 24, 2020
July 24, 2020 — CeloNova BioSciences Inc. announced it successfully completed enrollment of the COBRA REDUCE randomized...
The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. Getty Images 

Feature | Coronavirus (COVID-19) | June 15, 2020 | Dave Fornell, Editor
June 15, 2020 — The U.S. Food and Drug Administration (FDA) today revoked the emergency use authorization (EUA) that...
Videos | Coronavirus (COVID-19) | May 28, 2020
Interview with Andrew D. Krahn, M.D.,FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of...
WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19. #COVID19 #SARScov2 #Hydroxychloroquine
Feature | Coronavirus (COVID-19) | May 27, 2020
May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine...
Videos | Coronavirus (COVID-19) | May 18, 2020
Marianne Pop, Pharm.D., BCPS, a clinical pharmacist and clinical assistant professor with the regional pharmacy program...
Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

Icosapent Ethyl (Vascepa) significantly reduces revascularizations in statin patients based on data from the REDUCE-IT REVASC analyses, presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals | May 17, 2020
May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy....